GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41406229.
- Also identified by DOI 10.1126/sciadv.adv1434 and PMC identifier 13142706.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Genome-wide association studies have identified <i>Glycoprotein Nmb</i> (<i>GPNMB</i>) as a risk factor for Parkinson's disease. The risk allele increases <i>GPNMB</i> transcription and GPNMB protein levels in the CSF highlighting GPMNB as a potential biomarker for Parkinson's disease. However, a lack of knowledge of GPNMB's function and mechanism of secretion has hindered an interpretation of secreted GPNMB levels. In this study, we assessed the mechanism of GPNMB secretion by macrophages, the primary cell type expressing GPNMB in the brain. We show that GPNMB is secreted in response to lysosomal stress via lysosomal exocytosis and highlight the Parkinson's disease risk factor LRRK2 as a strong modulator of GPNMB secretion.
Medical subject headings
- Lysosomes
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
- Exocytosis
- Membrane Glycoproteins